Clinical Trial Update: Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

View source ↗

Summary

Post-marketing surveillance study of Lucentis (ranibizumab) for retinopathy of prematurity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Retinopathy of Prematurity | Status: COMPLETED